Novo Nordisk Valuation
| NVO Stock | USD 78.79 0.21 0.27% |
At this time, the firm appears to be overvalued. Novo Nordisk AS secures a last-minute Real Value of $70.61 per share. The latest price of the firm is $78.79. Our model forecasts the value of Novo Nordisk AS from analyzing the firm fundamentals such as Profit Margin of 0.35 %, return on equity of 0.81, and Current Valuation of 364.08 B as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Novo Nordisk's price fluctuation is very steady at this time. Calculation of the real value of Novo Nordisk AS is based on 3 months time horizon. Increasing Novo Nordisk's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Novo Nordisk is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novo Stock. However, Novo Nordisk's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 78.79 | Real 70.61 | Hype 79.0 | Naive 73.97 |
The intrinsic value of Novo Nordisk's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Novo Nordisk's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Novo Nordisk AS helps investors to forecast how Novo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novo Nordisk more accurately as focusing exclusively on Novo Nordisk's fundamentals will not take into account other important factors: Novo Nordisk Total Value Analysis
Novo Nordisk AS is now anticipated to have company total value of 364.08 B with market capitalization of 357.03 B, debt of 102.79 B, and cash on hands of 37.47 B. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Novo Nordisk fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
364.08 B | 357.03 B | 102.79 B | 37.47 B |
Novo Nordisk Investor Information
The company has Price/Earnings To Growth (PEG) ratio of 1.24. Novo Nordisk AS last dividend was issued on the 31st of March 2025. The entity had 2:1 split on the 20th of September 2023. Novo Nordisk AS is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Novo Nordisk Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Novo Nordisk has an asset utilization ratio of 62.35 percent. This suggests that the Company is making $0.62 for each dollar of assets. An increasing asset utilization means that Novo Nordisk AS is more efficient with each dollar of assets it utilizes for everyday operations.Novo Nordisk Ownership Allocation
Novo Nordisk AS maintains a total of 3.36 Billion outstanding shares. Roughly 89.77 % of Novo Nordisk outstanding shares are held by general public with 10.23 % by institutional investors. Please note that on December 18, 2024, Representative Michael McCaul of US Congress acquired $50k to $100k worth of Novo Nordisk AS's common stock.Novo Nordisk Profitability Analysis
The company reported the last year's revenue of 290.4 B. Total Income to common stockholders was 100.99 B with profit before taxes, overhead, and interest of 246.84 B.Novo Nordisk Past Distributions to stockholders
About Novo Nordisk Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Novo Nordisk AS. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Novo Nordisk AS based exclusively on its fundamental and basic technical indicators. By analyzing Novo Nordisk's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Novo Nordisk's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Novo Nordisk. We calculate exposure to Novo Nordisk's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Novo Nordisk's related companies.Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Novo Nordisk is traded on New York Stock Exchange in the United States.
A single share of Novo Nordisk represents a small ownership stake in the entity. As a stockholder of Novo, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Novo Nordisk Dividends Analysis For Valuation
There are various types of dividends Novo Nordisk can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Novo shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Novo Nordisk AS directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Novo pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Novo Nordisk by the value of the dividends paid out.
Novo Nordisk Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 4.5 B | |
| Quarterly Earnings Growth Y O Y | 0.292 | |
| Forward Price Earnings | 20.1207 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.